Table 4. Somatic mutations in each subtype.
| Somatic mutations | EBV (N=7) | MSI (N=19) | CIN (N=46) | GS (N=35) | P value | ||||
|---|---|---|---|---|---|---|---|---|---|
| Cases | (%) | Cases | (%) | Cases | (%) | Cases | (%) | ||
| TP53 | 0 | 0.0% | 5 | 26.3% | 26 | 56.5% | 10 | 28.6% | 0.003a |
| ACVR1B | 0 | 0.0% | 1 | 5.3% | 1 | 2.2% | 0 | 0.0% | 0.534 |
| ALK | 0 | 0.0% | 3 | 15.8% | 2 | 4.3% | 1 | 2.9% | 0.232 |
| APC | 2 | 28.6% | 1 | 5.3% | 8 | 17.4% | 1 | 2.9% | 0.050 |
| ARID1A | 4 | 57.1% | 14 | 73.7% | 12 | 26.1% | 9 | 25.7% | 0.000a |
| BCOR | 1 | 14.3% | 9 | 47.4% | 2 | 4.3% | 0 | 0.0% | 0.016a |
| BRAF | 0 | 0.0% | 3 | 15.8% | 0 | 0.0% | 0 | 0.0% | 0.003a |
| CBWD1 | 0 | 0.0% | 0 | 0.0% | 1 | 2.2% | 1 | 2.9% | 1.000 |
| CCND1 | 0 | 0.0% | 3 | 15.8% | 2 | 4.3% | 2 | 5.7% | 0.323 |
| CD274 | 1 | 14.3% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0.065 |
| CDH1 | 3 | 42.9% | 1 | 5.3% | 3 | 6.5% | 4 | 11.4% | 0.052 |
| CIC | 0 | 0.0% | 5 | 26.3% | 3 | 6.5% | 2 | 5.7% | 0.082 |
| CR1 | 0 | 0.0% | 5 | 26.3% | 2 | 4.3% | 8 | 22.9% | 0.220 |
| CTNNB1 | 1 | 14.3% | 2 | 10.5% | 0 | 0.0% | 2 | 5.7% | 0.054 |
| EGFR | 0 | 0.0% | 4 | 21.1% | 0 | 0.0% | 1 | 2.9% | 0.005a |
| ERBB2 | 0 | 0.0% | 5 | 26.3% | 2 | 4.3% | 1 | 2.9% | 0.028a |
| ERBB3 | 0 | 0.0% | 5 | 26.3% | 2 | 4.3% | 2 | 5.7% | 0.049a |
| FBXW7 | 0 | 0.0% | 3 | 15.8% | 3 | 6.5% | 1 | 2.9% | 0.301 |
| FGFR2 | 0 | 0.0% | 2 | 10.5% | 0 | 0.0% | 0 | 0.0% | 0.057 |
| HLA-B | 0 | 0.0% | 3 | 15.8% | 2 | 4.3% | 0 | 0.0% | 0.088 |
| IRF2 | 0 | 0.0% | 2 | 10.5% | 1 | 2.2% | 1 | 2.9% | 0.429 |
| JAK2 | 0 | 0.0% | 1 | 5.3% | 1 | 2.2% | 0 | 0.0% | 0.534 |
| KDR | 0 | 0.0% | 3 | 15.8% | 1 | 2.2% | 0 | 0.0% | 0.046a |
| KRAS | 0 | 0.0% | 5 | 26.3% | 1 | 2.2% | 0 | 0.0% | 0.002a |
| LARP4B | 0 | 0.0% | 3 | 15.8% | 1 | 2.2% | 0 | 0.0% | 0.046a |
| MDM2 | 0 | 0.0% | 1 | 5.3% | 0 | 0.0% | 0 | 0.0% | 0.243 |
| MEDAG | 0 | 0.0% | 2 | 10.5% | 0 | 0.0% | 0 | 0.0% | 0.057 |
| MLH1 | 0 | 0.0% | 2 | 10.5% | 0 | 0.0% | 0 | 0.0% | 0.057 |
| MSH2 | 0 | 0.0% | 4 | 21.1% | 1 | 2.2% | 0 | 0.0% | 0.009a |
| MTOR | 0 | 0.0% | 3 | 15.8% | 3 | 6.5% | 0 | 0.0% | 0.111 |
| MVK | 0 | 0.0% | 4 | 21.1% | 0 | 0.0% | 0 | 0.0% | 0.002a |
| MYC | 1 | 14.3% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0.065 |
| PGM5 | 1 | 14.3% | 4 | 21.1% | 0 | 0.0% | 0 | 0.0% | 0.001a |
| PIK3CA | 2 | 28.6% | 7 | 36.8% | 1 | 2.2% | 0 | 0.0% | 0.000a |
| PTEN | 0 | 0.0% | 2 | 10.5% | 0 | 0.0% | 1 | 2.9% | 0.096 |
| RHOA | 2 | 28.6% | 1 | 5.3% | 2 | 4.3% | 4 | 11.4% | 0.139 |
| SMAD4 | 0 | 0.0% | 1 | 5.3% | 1 | 2.2% | 0 | 0.0% | 0.534 |
| STK11 | 0 | 0.0% | 1 | 5.3% | 1 | 2.2% | 0 | 0.0% | 0.534 |
| ZBTB20 | 0 | 0.0% | 5 | 26.3% | 0 | 0.0% | 0 | 0.0% | 0.000a |
| Mutation rate | 2.6 | 6.6 | 1.8 | 1.5 | |||||
ap value less than 0.05.
Abbreviations: CIN, chromosomal instability, EBV, Epstein-Barr virus; GS, genomically stable; MSI, microsatellite instability. Fisher`s exact test was performed to evaluate differences in the respective proportions of somatic mutations between subgroups.